USA DOMESTIC SHIPPING (WAREHOUSE 4)
cRowX Labs, Tirzerow (Tirzepatide, Dual GIP and GLP-1 Receptor Agonist) 5mg/vial.
Tirzepatide (Tirzerow cRowX Labs) 5mg in vial is an antidiabetic medication used for the treatment of type 2 diabetes and for weight loss, classified as: Dual GIP and GLP-1 Receptor Agonist. Tirzepatide is administered through subcutaneous injection (under the skin). Tirzepatide is a synthetic peptide with glucose-lowering effects. It works to stimulate first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.
Tirzepatide was approved for medical use in the United States in May 2022, in the European Union in September 2022, in Canada in November 2022 and in Australia in December 2022.The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. It was approved by the FDA for weight loss in November 2023!
Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes. Tirzepatide can increase insulin sensitivity.
Tirzepatide (Tirzerow cRowX Labs) 5mg in vial is an antidiabetic medication used for the treatment of type 2 diabetes and for weight loss. Tirzepatide is administered through subcutaneous injection (under the skin)
Tirzepatide was approved for medical use in the United States in May 2022, in the European Union in September 2022, in Canada in November 2022 and in Australia in December 2022.The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. It was approved by the FDA for weight loss in November 2023!
Reviews
There are no reviews yet.